Serum CD163 and TARC as Disease Response Biomarkers in Classical Hodgkin Lymphoma

被引:89
作者
Jones, Kimberley [1 ,2 ]
Vari, Frank [1 ]
Keane, Colm [1 ,3 ,4 ]
Crooks, Pauline [1 ]
Nourse, Jamie P. [1 ]
Seymour, Louise A. [1 ,2 ,3 ]
Gottlieb, David [5 ]
Ritchie, David [6 ,7 ]
Gill, Devinder [2 ,3 ]
Gandhi, Maher K. [1 ,2 ,3 ]
机构
[1] QIMR, Clin Immunohaematol Lab, Brisbane, Qld 4006, Australia
[2] Univ Queensland, Sch Med, Brisbane, Qld, Australia
[3] Princess Alexandra Hosp, Dept Haematol, Brisbane, Qld 4102, Australia
[4] Griffith Univ, Gold Coast, Australia
[5] Univ Sydney, Westmead Millennium Inst, Westmead, NSW 2145, Australia
[6] Peter MacCallum Canc Ctr, Dept Haematol, Melbourne, Vic, Australia
[7] Univ Melbourne, Melbourne, Vic, Australia
基金
英国医学研究理事会;
关键词
TUMOR-ASSOCIATED MACROPHAGES; EPSTEIN-BARR-VIRUS; ACTIVATION-REGULATED CHEMOKINE; PROGNOSTIC SCORE; CC-CHEMOKINE; EBV DNA; CHEMOTHERAPY; MARKERS; THYMUS; IDENTIFICATION;
D O I
10.1158/1078-0432.CCR-12-2693
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Candidate circulating disease response biomarkers for classical Hodgkin lymphoma (cHL) might arise from Hodgkin-Reed-Sternberg (HRS) cells or nonmalignant tumor-infiltrating cells. HRS cells are sparse within the diseased node, whereas benign CD163(+) M2 tissue-associated macrophages (TAM) are prominent. CD163(+) cells within the malignant node may be prognostic, but there is no data on serum CD163 (sCD163). The HRS-specific serum protein sTARC shows promise as a disease response biomarker. Tumor-specific and tumor-infiltrating circulating biomarkers have not been compared previously. Experimental Design: We prospectively measured sCD163 and sTARC in 221 samples from 47 patients with Hodgkin lymphoma and 21 healthy participants. Blood was taken at five fixed time-points prior, during, and after first-line therapy. Results were compared with radiological assessment and plasma Epstein-Barr virus DNA (EBV-DNA). Potential sources of circulating CD163 were investigated, along with immunosuppressive properties of CD163. Results: Pretherapy, both sCD163 and sTARC were markedly elevated compared with healthy and complete remission samples. sCD163 better reflected tumor burden during therapy, whereas sTARC had greater value upon completion of therapy. sCD163 correlated with plasma EBV-DNA, and associated with B symptoms, stage, and lymphopenia. Circulating CD163(+) monocytes were elevated in patients, indicating that sCD163 are likely derived from circulating and intratumoral cells. Depletion of cHL CD163(+) monocytes markedly enhanced T-cell proliferation, implicating monocytes and/or TAMs as potential novel targets for immunotherapeutic manipulation. Conclusion: The combination of circulating tumor-infiltrate (sCD163) and tumor-specific (sTARC) proteins is more informative than either marker alone as disease response biomarkers in early and advanced disease during first-line therapy for cHL. Clin Cancer Res; 19(3); 731-42. (C) 2012 AACR.
引用
收藏
页码:731 / 742
页数:12
相关论文
共 43 条
  • [1] Lack of association of tumor-associated macrophages with clinical outcome in patients with classical Hodgkin's lymphoma
    Azambuja, D.
    Natkunam, Y.
    Biasoli, I.
    Lossos, I. S.
    Anderson, M. W.
    Morais, J. C.
    Spector, N.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 (03) : 736 - 742
  • [2] End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin's lymphoma
    Barnes, J. A.
    LaCasce, A. S.
    Zukotynski, K.
    Israel, D.
    Feng, Y.
    Neuberg, D.
    Toomey, C. E.
    Hochberg, E. P.
    Canellos, G. P.
    Abramson, J. S.
    [J]. ANNALS OF ONCOLOGY, 2011, 22 (04) : 910 - 915
  • [3] Tumor-Associated Macrophages in Pediatric Classical Hodgkin Lymphoma: Association with Epstein-Barr Virus, Lymphocyte Subsets, and Prognostic Impact
    Barros, Mario Henrique M.
    Hassan, Rocio
    Niedobitek, Gerald
    [J]. CLINICAL CANCER RESEARCH, 2012, 18 (14) : 3762 - 3771
  • [4] Tumor microenvironment composition in pediatric classical Hodgkin lymphoma is modulated by age and Epstein-Barr virus infection
    Barros, Mario Henrique M.
    Vera-Lozada, Gabriela
    Soares, Fernando A.
    Niedobitek, Gerald
    Hassan, Rocio
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2012, 131 (05) : 1142 - 1152
  • [5] BONADONNA G, 1975, CANCER, V36, P252, DOI 10.1002/1097-0142(197507)36:1<252::AID-CNCR2820360128>3.0.CO
  • [6] 2-7
  • [7] Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas
    Cheson, BD
    Horning, SJ
    Coiffier, B
    Shipp, MA
    Fisher, RI
    Connors, JM
    Lister, TA
    Vose, J
    Grillo-López, A
    Hagenbeek, A
    Cabanillas, F
    Klippensten, D
    Hiddemann, W
    Castellino, R
    Harris, NL
    Armitage, JO
    Carter, W
    Hoppe, R
    Canellos, GP
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) : 1244 - 1253
  • [8] Revised response criteria for malignant lymphoma
    Cheson, Bruce D.
    Pfistner, Beate
    Juweid, Malik E.
    Gascoyne, Randy D.
    Specht, Lena
    Horning, Sandra J.
    Coiffier, Bertrand
    Fisher, Richard I.
    Hagenbeek, Anton
    Zucca, Emanuele
    Rosen, Steven T.
    Stroobants, Sigrid
    Lister, T. Andrew
    Hoppe, Richard T.
    Dreyling, Martin
    Tobinai, Kensei
    Vose, Julie M.
    Connors, Joseph M.
    Federico, Massimo
    Diehl, Volker
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) : 579 - 586
  • [9] Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome
    Chetaille, Bruno
    Bertucci, Francois
    Finetti, Pascal
    Esterni, Benjamin
    Stamatoullas, Aspasia
    Picquenot, Jean Michel
    Copin, Marie Christine
    Morschhauser, Frank
    Casasnovas, Olivier
    Petrella, Tony
    Molina, Thierry
    Vekhoff, Anne
    Feugier, Pierre
    Bouabdallah, Reda
    Birnbaum, Daniel
    Olive, Daniel
    Xerri, Luc
    [J]. BLOOD, 2009, 113 (12) : 2765 - 2775
  • [10] Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy
    DeNardo, David G.
    Brennan, Donal J.
    Rexhepaj, Elton
    Ruffell, Brian
    Shiao, Stephen L.
    Madden, Stephen F.
    Gallagher, William M.
    Wadhwani, Nikhil
    Keil, Scott D.
    Junaid, Sharfaa A.
    Rugo, Hope S.
    Hwang, E. Shelley
    Jirstroem, Karin
    West, Brian L.
    Coussens, Lisa M.
    [J]. CANCER DISCOVERY, 2011, 1 (01) : 54 - 67